心肌梗死后猝死率变化:VALIANT与PARADISE-MI试验的启示
本研究为对PARADISE-MI和VALIANT两项多中心随机临床试验的二次分析,比较AMI后伴肺淤血和/或左室功能不全患者的猝死/复苏性心脏骤停(RCA)发生率。结果显示,PARADISE-MI试验中猝死/RCA发生率为2.6%,而VALIANT试验中类似特征人群为7.4%;两试验中猝死率均在梗死后第一个月最高,随后迅速下降。与20年前相比,现代管理下左室射血分数降低和/或肺淤血患者的猝死/RCA率降低了2-3倍。
要点
- AMI后第一个月猝死/RCA风险最高,随后迅速下降。
- 现代管理下猝死/RCA率较20年前降低2-3倍。
- 需加强梗死后第一个月高危患者的保护性干预。
核心结论
- AMI后猝死/RCA风险在第一个月最高,随后迅速下降。
- 与20年前相比,现代管理下左室射血分数降低和/或肺淤血患者的猝死/RCA率降低2-3倍。
- 需要干预措施以进一步保护梗死后第一个月的高危患者。
研究设计与样本
- 研究设计:对多中心随机临床试验的二次分析。
- PARADISE-MI队列纳入5661例患者,平均年龄63.7岁,男性4298例(75.9%)。
- VALIANT(PARADISE-MI样)队列纳入9617例患者,平均年龄66.1岁,男性6504例(67.6%)。
- VALIANT试验入组时间1998年12月至2001年6月,PARADISE-MI试验入组时间2016年12月至2020年3月;中位随访分别为24.7个月和22个月。
主要发现
- VALIANT(PARADISE-MI样)队列中707/9617例(7.4%)发生猝死/RCA。
- PARADISE-MI试验中148/5661例(2.6%)发生猝死/RCA。
- 两试验中猝死率均在梗死后第一个月最高:VALIANT为19.3(95%CI 16.4-22.6)/100人年,PARADISE-MI为9.5(95%CI 7.0-12.7)/100人年,随后稳步下降。
- 与VALIANT队列相比,PARADISE-MI试验中患者更常接受PCI治疗,并更频繁使用β受体阻滞剂、他汀和盐皮质激素受体拮抗剂。
临床怎么用
- 临床应关注AMI后第一个月内猝死/RCA高风险患者的监测与保护性干预。
- 现代管理(包括PCI、β受体阻滞剂、他汀、盐皮质激素受体拮抗剂)与猝死/RCA风险降低相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sudden death is a leading cause of death after acute myocardial infarction (AMI). The Prospective ARNi vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI (PARADISE-MI) and Valsartan in Acute Myocardial Infarction (VALIANT) trials enrolled patients with pulmonary congestion and/or left ventricular dysfunction after AMI. Whether the prognosis in such patients has changed over time has not been examined. OBJECTIVE: To compare the rate of sudden death/resuscitated cardiac arrest (RCA) after AMI in the PARADISE-MI and VALIANT trials. DESIGN, SETTING, AND PARTICIPANTS: This was a secondary analysis of multicenter randomized clinical trials enrolling patients after AMI. In the primary analysis, the VALIANT cohort was restricted to patients with "PARADISE-MI-like" characteristics (eg, at least 1 augmenting risk factor and no history of heart failure). The baseline characteristics of people in both trials were compared. The VALIANT trial enrolled from December 1998 to June 2001, and the PARADISE-MI trial enrolled between December 2016, and March 2020. The median follow-up in the VALIANT and PARADISE-MI trials was 24.7 and 22 months, respectively. People with AMI, complicated by pulmonary congestion and/or left ventricular dysfunction, were included in the analysis. EXPOSURE: Sudden death after AMI. RESULTS: A total of 5661 patients were included in the PARADISE-MI cohort (mean [SD] age, 63.7 [11.5] years; 4298 male [75.9%]), 9617 were included in the VALIANT (PARADISE-MI-like) cohort (mean [SD] age, 66.1 [11.5] years; 6504 male [67.6%]), and 14 703 patients were included in the VALIANT (total) cohort (mean [SD] age, 64.8 [11.8] years; 10 133 male [68.9%]). In the PARADISE-MI-like cohort of the VALIANT trial, 707 of 9617 participants (7.4%) experienced sudden death/RCA. A total of 148 of 5661 people (2.6%) in the PARADISE-MI trial experienced sudden death/RCA. Sudden death rates were highest in the first month after infarction in both trials: 19.3 (95% CI, 16.4-22.6) per 100 person-years in the VALIANT trial and 9.5 (95% CI, 7.0-12.7) per 100 person-years in the PARADISE-MI trial, and these rates declined steadily thereafter. Compared with the VALIANT cohort, people in the PARADISE-MI trial were more often treated with percutaneous coronary intervention for their qualifying AMI and received a β-blocker, statin, and mineralocorticoid receptor antagonist more frequently. CONCLUSIONS AND RELEVANCE: After AMI, the risk of sudden death/RCA was highest in the first month, declining rapidly thereafter. Results revealed that compared with counterparts from 20 years ago, the rate of sudden death/RCA in patients with a reduced left ventricular ejection fraction and/or pulmonary congestion was 2- to 3-fold lower in people receiving contemporary management. Interventions to further protect people in the highest risk first month after infarction are needed. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02924727.
引用
- Curtain, Pfeffer, Braunwald, et al. Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI Trials. JAMA Cardiol. 2024. PMID: 39110471. doi:10.1001/jamacardio.2024.2356
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。